First cancer center in Oklahoma and fourth VA medical center to offer
advanced MRI-guided radiation therapy to treat cancer.
DENVER, June 13,
2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY)
announced today that the VA Oklahoma City Healthcare System has
selected MRIdian MRI-guided radiation therapy system to expand
radiation therapy services at the Oklahoma City VA Medical Center.
This will be the first cancer center in Oklahoma and the fourth VA medical center
offering Veterans access to MRIdian's advanced MRI-guided radiation
therapy to treat cancer. The MRIdian system will enable the
Oklahoma City VA Medical Center to provide precision MRI-guided
radiation therapy technology to Veterans seeking personalized
treatment for a broad range of cancer, including pancreas,
prostate, lung, liver, breast, and oligometastatic disease. Other
VA medical centers that will be offering MRIdian MRI-guided
radiation therapy include Louis Stokes Cleveland Medical Center (VA
Northeast Ohio Healthcare System), Lt. Colonel Charles S. Kettles
VA Medical Center (VA Ann Arbor Healthcare System), and Michael E.
DeBakey Medical Center (VA Houston Healthcare system).
The Veterans Health Administration is America's largest
integrated healthcare system, providing care at 1,298 healthcare
facilities, including 171 medical centers. The VA is leading the
fight against cancer through precision oncology by developing and
applying new technologies, tools, research knowledge, and
best-practice therapies. Their scientific and medical breakthroughs
are shared inside and outside their healthcare system to benefit
Veterans and all Americans.
"ViewRay is proud to be working with VA Oklahoma City Healthcare
System, a talented group of clinicians committed to bringing
patients the benefit of precise and personalized radiation
therapy," said Paul Ziegler, ViewRay
Executive Vice President and CCO. "We are excited to see another VA
healthcare system join the growing MRIdian community. Expanding the
availability of MRIdian's short-course non-invasive therapy with
fewer side effects and better quality of life is an important
advancement for our Veterans."
The MRIdian system provides oncologists with outstanding
anatomical visualization through diagnostic-quality MR images and
the ability to adapt a radiation therapy plan to the targeted
cancer with the patient on the table. This combination allows
physicians to define tight treatment margins to avoid unnecessary
radiation exposure of vulnerable organs-at-risk and healthy tissue
and allows the delivery of ablative radiation doses in five or
fewer treatment sessions without relying on implanted markers.
MRIdian enables automatic gating of the radiation beam if the
target moves outside the user-defined margins by providing
continuous real-time tracking of the target and organs at risk.
This allows for delivering the prescribed dose to the target while
sparing surrounding healthy tissue and critical structures. This
results in minimizing toxicities typically associated with
conventional radiation therapy.
To date, over 31,000 patients have been treated with MRIdian.
Currently, 62 MRIdian systems are installed at hospitals around the
world, where they are used to treat a wide variety of solid tumors
and are the focus of numerous ongoing research efforts. MRIdian has
been the subject of hundreds of peer-reviewed publications,
scientific meeting abstracts, and presentations. For a list of
treatment centers, please visit:
https://viewray.com/mridian-treatment-centers/
Disclaimer:
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
Safety Statement
The MRIdian Linac System is not
appropriate for all patients, including those who are not
candidates for magnetic resonance imaging. Radiation treatments may
cause side effects that can vary depending on the part of the body
being treated. The most frequent ones are typically temporary and
may include, but are not limited to, irritation to the respiratory,
digestive, urinary, or reproductive systems; fatigue; nausea; skin
irritation; and hair loss. In some patients, side effects can be
severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should
discuss the potential for side effects and their severity as well
as the benefits of radiation and magnetic resonance imaging with
your doctor to make sure radiation treatment is right for you.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the
MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon
a proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was
purpose-built to address specific challenges, including beam
distortion, skin toxicity, and other concerns that potentially may
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Private Securities Litigation Reform
Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, ViewRay's financial
guidance for the full year 2023, anticipated future
orders, anticipated future operating and financial
performance, treatment results, therapy adoption, innovation, and
the performance of the MRIdian systems. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to commercialize the MRIdian Linac System, demand for
ViewRay's products, the ability to convert backlog into revenue,
the timing of delivery of ViewRay's products, the timing, length,
and severity of the COVID-19 pandemic, including its impacts across
our businesses on demand, our operations and global supply chains,
the results and other uncertainties associated with clinical
trials, the ability to raise the additional funding needed to
continue to pursue ViewRay's business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, competition in the industry in which
ViewRay operates, and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2022 and its Quarterly Reports on Form 10-Q, as updated
periodically with the Company's other filings with the SEC. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original
content:https://www.prnewswire.com/news-releases/va-oklahoma-city-healthcare-system-chooses-viewrays-mridian-mri-guided-radiation-therapy-system-301849016.html
SOURCE ViewRay, Inc.